Aspen Pharmacare Holdings (JSE:APN) ROCE %: 3.42% (As of Dec. 2025)


JSE:APN Aspen Pharmacare Holdings Ltd JSE:APN
73 GF Score
Price R154.85
GF Value R178.17
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings ROCE %?

Aspen Pharmacare Holdings JSE:APN +0.66% 73 ROCE % is 3.42% as of Dec. 2025. GuruFocus rates JSE:APN with a GF Score™ of 73/100 and a GF Value™ of R178.17 (Modestly Undervalued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aspen Pharmacare Holdings's annualized ROCE % for the quarter that ended in Dec. 2025 was 3.42%.

Aspen Pharmacare Holdings  (JSE:APN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aspen Pharmacare Holdings ROCE % Related Terms

Aspen Pharmacare Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Aspen Pharmacare Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspen Pharmacare Holdings ROCE % Chart

Aspen Pharmacare Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.65 11.06 7.91 7.03 1.31

Aspen Pharmacare Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.85 7.00 4.86 -2.22 3.42
JSE:APN
73GF Score
Aspen Pharmacare Holdings Ltd JSE:APN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspen Pharmacare Holdings ROCE % Calculation

Aspen Pharmacare Holdings's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=1526/( ( (139063 - 24302) + (135893 - 17496) )/ 2 )
=1526/( (114761+118397)/ 2 )
=1526/116579
=1.31 %

Aspen Pharmacare Holdings's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=3950/( ( (135893 - 17496) + (128045 - 15770) )/ 2 )
=3950/( ( 118397 + 112275 )/ 2 )
=3950/115336
=3.42 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 3.42% mean?
Aspen Pharmacare Holdings (JSE:APN) has a ROCE % of 3.42% as of Dec. 2025.
Is Aspen Pharmacare Holdings' ROCE % too high?
Aspen Pharmacare Holdings' current ROCE % is 3.42%. The Drug Manufacturers industry median ROCE % is 7.00. Aspen Pharmacare Holdings' value of 3.42% is 51.1% below this industry median. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' ROCE % compare to ZTS and UTHR?
Aspen Pharmacare Holdings' ROCE % of 3.42% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Aspen Pharmacare Holdings' value of 3.42% is 51.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current ROCE % of 3.42% is 51.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current ROCE % is 3.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R178.17, compared to a current price of R154.85 — trading 13.1% below its estimated fair value. The current ROCE % is 3.42% and 51.1% below the Drug Manufacturers industry median of 7.00. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current ROCE % is 3.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of R154.85 is trading 13.1% below its estimated GF Value™ of R178.17. GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.

Key valuation signals for JSE:APN:

  • ROCE %: 3.42%
  • GF Value™: R178.17 vs. price of R154.85 (13.1% below fair value)
  • GF Score™: 73/100 with 10 warning signs
  • Industry Position: 51.1% below the Drug Manufacturers median

No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score

Get the complete analysis for JSE:APN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R154.85
Price
R178.17
GF Value